



NUMERAL LTD

(Formerly Go Life International Ltd)

(Incorporated in the Republic of Mauritius)

(Registration number: 098177 C1/GBL)

Primary Listing SEM share code: GOLI.N0000

Secondary Listing JSE share code: XII

ISIN: MU0330N00004

("the Company" or "Numeral" or "the Group")

UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 AUGUST 2025

DIRECTORS' COMMENTARY

BACKGROUND

The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act and holds a Global Business Licence issued by the Mauritius Financial Services Commission.

Numeral is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius ("SEM") on 7 July 2011. The Company completed a secondary listing on the Alternative Exchange ("AltX") of the Johannesburg Stock Exchange Limited ("the JSE") on 23 November 2016.

During the prior year, the Company recovered its 50% interest in Cryo-Save South Africa Proprietary Limited ("Cryo-Save"), as detailed in the Company's original announcement dated 18 December 2020 wherein the Company (formerly known as Go Life) advised that it had added Cryo-Save to its group of companies. The recovery of the interest was for no consideration. The Company had effective control over the Cryo-Save operations from 1 September 2024 and thus the comparative numbers for Q1 do not include any numbers relating to Cryo-Save.

It is also noted that this is the first time in a number of years that the Company is reporting interim results as a group and the prior period numbers will not be strictly comparable.

The main focus of the Group remains on biotechnology, health and pharmaceuticals.

During 2024, a new South African subsidiary, Numeral Financial Services Proprietary Limited ("NFS"), was set up at no cost to the Company. NFS is a licensed Financial Services Provider, registered as a Category 1 and Category 2 asset manager (FSP 54132), and is also accredited with the National Credit Regulator (NCR CP 21170). Operations were placed on hold during the previous period as NFS was not part of the business plan as approved by SEM. NFS is currently dormant, however, it will form a key component of Numeral's long-term strategy as detailed under Prospects below.

ACQUISITIONS AND DISPOSALS

The following acquisitions and organic growth have been implemented during the period under review:

- Numeral acquired an additional 1% interest in Cryo-Save on 1 March 2025. This takes Numeral to 51% shareholding in Cryo-Save.
- Numeral acquired an effective 51% shareholding in Longevity Lab Proprietary Limited ("Longevity") with effect from 1 March 2025 through an issue of ordinary shares in Longevity for cash of R800 000.
- Numeral acquired an effective 40% shareholding in Isopharm Proprietary Limited ("Isopharm") with effect from 15 May 2025 through an issue of ordinary shares in Isopharm for cash of R350 000.
- Numeral established a new entity named Celerevive Proprietary Limited ("Celerevive") during the 2025 financial year of which it sold 49% to the Celerevive management team on 1 March 2025. Operations commenced in May 2025.

There were no further acquisitions or disposals during the period under review.

RELATED PARTIES

There were no transactions with related parties during the period under review that are material to these results.

BASIS OF PREPARATION

These results have been prepared in accordance with International Financial Reporting Standards (IFRS®), IAS 34: Interim Reporting, the SEM Listings Rules and the JSE Listings Requirements. The accounting policies adopted in the preparation of these Q2 results are in terms of IFRS® and are consistent with those applied in the preparation of the audited financial statements for the year ended 28 February 2025.

These results have been prepared by Mr JD Botma.

EVENTS AFTER THE REPORTING PERIOD

There were no material subsequent events after 31 August 2025.

PROSPECTS

Numeral is dedicated to regrowing its healthcare and biotech business as well as embracing technological and commercial opportunities in the biotech and pharmaceutical vertical. It will also seek to diversify the Group through strategic acquisitions and pursuing new distribution channels through innovative platforms and strategic partnerships.

Numeral has undertaken a consolidation of its SA operating entities under a central SA holding company, named Numerale SA Holdings Proprietary Limited ("NSH"), established on 18 March 2025, which will be effective in the 2026 financial year.

Numeral also established Numerale Treasury Solutions Limited on 19 April 2025, to house the Domestic Medium-Term Note ("DMTN") program in preparation for its debt listing on the Johannesburg Stock Exchange, which will take place in the 2026 financial year.

Numeral established Qantara Private Capital Proprietary Limited ("Qantara") as a 100% held subsidiary of Numerale Financial Services Proprietary Limited ("NFS") on 8 April 2025. Qantara established three Shariah compliant, ethically aligned private equity funds namely: the Qantara Income Fund, the Qantara Growth Fund and the Qantara Property Fund, each as *en commandite* partnerships.

Numeral established Numerale DRC Holdings ("NDRCH") in preparation for its future expansion of operations into the Democratic Republic of Congo. Our intention is to only activate operations in this entity in the second half of the 2026 financial year.

At the stage when a strategic acquisition is undertaken, in meeting the requirements, the Company will issue a listing circular, incorporating revised listing particulars, in accordance with the SEM Listings Rules and the JSE Listings Requirements. The information regarding the prospects of the Company included in this section, including any forward-looking information, were not audited or reviewed by the Company's auditors.

GOING CONCERN

The Group has started to show profits, is generating cash and retains the ongoing support of key shareholders.

DIVIDENDS

No dividends were authorised or paid during the period under review.

DIRECTORS

Mr Jacobus Botma was appointed to the Board as an Executive Financial Director with effect from 29 September 2025. There were no other changes to the Board of Directors during the period under review.

QUARTERLY INFORMATION

The Company is required to publish quarterly and interim financial results for the six months ended 31 August 2025 in terms of the Listing Rule 12.19 of the SEM. The abridged unaudited quarterly and interim financial statements ("QFS") have been prepared in accordance with the measurement and recognition requirements of International Financial Reporting Standards ("IFRS") and the SEM Listing Rules and the JSE Listings Requirements.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION – UNAUDITED QUARTERLY AND INTERIM INFORMATION

USD	Unaudited August 2025	Unaudited May 2025	Audited February 2025	Unaudited August 2024
ASSETS				
Non-current Assets	1 853 693	1 793 508	1 121 816	-
Deferred tax	365 134	358 214	346 460	-
Loan receivables	1 336 093	1 284 725	641 700	-
Property, Plant and Machinery	133 070	131 173	133 656	-
Investment in associates	19 396	19 396		-
Current Assets	1 617 348	1 369 275	1 665 178	238 475
Trade and other receivables	1 280 843	1 067 335	895 482	212 256
Cash and Cash Equivalents	143 232	136 223	212 662	26 219
Inventory	54 297	45 630	32 689	
Loan receivables	138 976	120 087	524 345	
TOTAL ASSETS	3 471 041	3 162 783	2 786 994	238 475
EQUITY				
Capital and Reserves	(1 824 019)	(1 894 098)	(1 992 079)	(24 763)
Share Capital	7 926 898	7 926 898	7 926 898	28 460 357
Accumulated Loss	(27 809 106)	(27 897 205)	(27 972 928)	(28 485 120)
Share premium	20 533 459	20 533 459	20 533 459	-
Other reserves	(1 443 782)	(1 443 782)	(1 443 782)	-
Non-controlling interest	(1 031 488)	(1 013 468)	(1 035 725)	-
LIABILITIES				
Non-current Liabilities	4 649 172	4 480 892	4 025 833	-
Deferred income	-	-	225 625	-
Borrowings	4 649 172	4 480 892	3 800 208	-
Current Liabilities	645 888	575 989	753 240	263 238
Loans from shareholders	-	-	-	132 282
Trade and other Payables	592 711	547 369	554 771	107 902
Amounts due to other related parties	-	-	-	23 054
Deferred income	43 829	25 022	19 908	-
Borrowings	-	-	171 031	-
Income tax liabilities	9 348	3 598	7 530	-
TOTAL EQUITY AND LIABILITIES	3 471 041	3 162 783	2 786 994	238 475

CONSOLIDATED STATEMENT OF PROFIT AND OTHER COMPREHENSIVE INCOME – UNAUDITED QUARTERLY AND INTERIM INFORMATION

USD	Unaudited 6 months to 31 August 2025	Unaudited 6 months to 31 August 2024	Unaudited 3 months to 31 May 2025	Unaudited 3 months to 31 May 2024	Audited Year ended 28 February 2025
Revenue	1 162 731	188 973	542 779	83 184	1 692 555
Expenses	(259 989)	(66 771)	(101 252)	(61 569)	(368 466)
Operating profit from operations	902 742	122 202	441 527	1 668	1 324 089
Administrative expenses	(24 335)	-	(16 612)	-	(47 874)
Other expenses	(691 325)	-	(348 682)	-	(804 248)
Foreign exchange gain/(loss)	7 859	-	3 087	-	(221 932)
Profit before taxation	194 941	122 202	79 320	1 668	250 035
Taxation	(9 348)	-	(3 598)	-	(68 101)
Net profit after taxation	185 593	122 202	75 722	1 668	181 934
Other Comprehensive income	-	-	-	-	-
Total comprehensive profit/loss for the period	185 593	122 202	75 722	1 668	181 934
Net profit attributed to:	185 593	122 202	75 722	1 668	181 934
Owners of the parent	130 968	-	53 465	-	168 786
Non-controlling interests	54 625	-	22 257	-	13 148
Total comprehensive income attributed to:	185 593	122 202	75 722	1 668	181 934
Owners of the parent	130 968	-	53 465	1 668	168 786
Non-controlling interests	54 625	-	22 257	-	13 148
Earnings per share based on weighted average shares	0.0105	0.0098	0.004	0.00013	0.014

CONSOLIDATED STATEMENT OF CASH FLOWS – UNAUDITED QUARTERLY INFORMATION

USD	Unaudited August 2025	Unaudited August 2024	Unaudited May 2025	Unaudited May 2024	Audited February 2025
Cash flows used in operating activities	161 288	(25 762)	661 649	(14 225)	(2 076 565)
Profit for the year	194 941	122 202	79 320	-	250 035
<i>Adjustment for:</i>					
Depreciation for property, plant and equipment	17 007	-	1 163	-	382 311
Consolidation adjustments	126 191	(15 853)	773 362	-	(2 145 370)
<i>Changes in working capital</i>					
Inventory	(8 667)	-	(12 941)	-	(32 689)
Other receivables	(213 508)	(170 301)	(171 853)	-	(895 482)
Other payables	45 324	38 190	(7 402)	-	364 327
Cash flows from financing activities	(238 537)	51 679	(527 909)	14 225	2 805 194
Repayments of loans from group companies	(70 257)	-	(238 767)	-	(1 166 045)
Repayments of financial liabilities at fair value	-	(2 795)	-	1 000	-
Proceeds from borrowings	(168 280)	54 474	(289 142)	13 225	3 971 239
Cash flows (used in)/generated from investing activities	7 819	-	2 483	-	(515 967)
Acquisition of property, plant and machinery	7 819	-	2 483	-	(515 967)
Net cash flow for period under review	(69 430)	25 916	(76 439)	-	212 359
Cash and cash equivalents at the beginning of the year	212 662	303	212 662	303	303
Cash and cash equivalents at the end of the year	143 232	26 219	136 223	303	212 662

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Figures in US Dollars	Share capital	Share premium	Accumulated loss	Consolidated reserves	Attributed to equity holders of Group	Non- controlling interest	Total equity
Balance at							
01 March 2024	7 926 898	20 533 459	(28 141 714)	-	318 644	(1 048 873)	(730 229)
Profit for the year	-	-	168 786	-	168 786	13 148	181 934
Other reserves arising on consolidation	-	-	-	(1 443 782)	(1 443 782)	-	(1 443 782)
Other comprehensive income	-	-	-	-	-	-	-
Balance at							
28 February 2025	7 926 898	20 533 459	(27 972 928)	(1 443 782)	(956 352)	(1 035 725)	(1 992 077)
Profit for the 6 months ended 31 August 2025	-	-	130 968	-	130 968	54 625	185 593
Balance at							
31 August 2025	7 926 898	20 533 459	(27 841 960)	(1 443 782)	(825 384)	(981 100)	(1 806 484)

CONDENSED SEGMENTAL INFORMATION

Segmental information is being presented for the first time and comparative information has not been published. The segmental information for the six months ended 31 August 2025 is set out below:

USD	Financial Services	Biotechnolog y	Holdings	Eliminations	Total
31 August 2025 (Unaudited)					
Total Revenue	165 713	997 018	41 000	(41 000)	1 162 731
- External Revenue	165 713	997 018	41 000	(41 000)	1 162 731
- Intersegment	-	-	-	-	-
Other income	-	-	-	-	-
Expenses	(103 093)	(885 539)	(29 507)	50 349	(967 790)
Operating profit(loss)	62 620	111 479	11 493	-	194 941
Net finance income	-	-	-	-	-
Profit/(loss) before tax	62 620	111 479	11 493	-	194 941
Taxation	-	-	-	-	(9 348)
Net profit/(loss) for the period	62 620	111 479	11 493	-	185 593
Attributable to parent	62 620	56 855	11 493	-	130 968
Revenue by region					
Mauritius	-	-	41 000	(41 000)	-
South Africa	165 713	997 018	-	-	1 162 731
Total	165 713	997 018	41 000	(41 000)	1 162 731
Total Assets	687 259	2 714 173	243 663	243 663	3 471 041
Total Liabilities	(609 644)	(4 575 248)	(238 785)	238 785	(5 295 060)
Capital expenditure	-	7 819	-	-	7 819

RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS

USD	Unaudited 6 months 31 August 2025	Unaudited 6 months 31 August 2024
Basic profit/(loss)	130 968	122 202
Headline earnings/(loss)	130 968	122 202
Weighted average number of shares (net of treasury shares)	1 242 500 000	1 242 500 000
Basic and diluted earnings/(loss) per share (USD cents)	0.0105	0.0098
Headline earnings/(loss) per share (USD cents)	0.0105	0.0098

AVAILABLE INFORMATION

Copies of the abridged unaudited interim results for the six months ended 31 August 2025 and the statement of direct and indirect interests of each officer of the Company, pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request to the at the registered office of the Company at Unit 13 Socota Phoenicia, Sayed Hossen Road, Phoenix Mauritius.

This communiqué is issued pursuant to SEM Listing Rules 11.3, 12.14 and 12.20 and section 88 of the Securities Act of Mauritius 2005 as well as the JSE Listings Requirements. The Board accepts full responsibility for the accuracy of the information contained in these abridged unaudited results. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 31 August 2025 that require any additional disclosure or adjustment to the Financial Statements.

Numeral has its primary listing on SEM and a secondary listing on the AltX of the JSE.

For and on Behalf of the Board

Mauritius

17 October 2025

Executive Directors:

David van Niekerk (CEO)
Neville Graham (COO)
Jacobus Botma

Non-Executive Directors:

Mohamed Yusuf Sooklall (MSK)
Dr Aansa Devi Bedacee

JSE Sponsor:

AcaciaCap Advisors Proprietary Limited

Management Company and Company Secretary:

LTS Management Services Limited
